CORRECTING and REPLACING Enzon to Present at BMO Focus on Healthcare Conference

BRIDGEWATER, N.J., Jul 28, 2009 (BUSINESS WIRE) -- In first graph of release dated July 27, 2009, date should be Wednesday, August 5 (sted Tuesday, August 4).

The corrected release reads:

ENZON TO PRESENT AT BMO FOCUS ON HEALTHCARE CONFERENCE

Enzon Pharmaceuticals, Inc. (Nasdaq: ENZN) announced today that Jeffrey H. Buchalter, Enzon's president and chief executive officer, will present at the 2009 BMO Capital Markets 9th Annual Focus on Healthcare Conference, which is being held August 5th in New York City. Enzon's presentation will take place at 9:30 a.m. EST on Wednesday, August 5, 2009. The presentation will be webcast. Interested parties can access the webcast information by going to the events page that is under shareholder information on Enzon's website at www.enzon.com.

About Enzon

Enzon Pharmaceuticals, Inc. is a biopharmaceutical company dedicated to the development, manufacturing, commercialization of important medicines for patients with cancer and other life-threatening conditions. Enzon has a portfolio of four marketed products, Oncaspar(R), DepoCyt(R), Abelcet(R) and Adagen(R). The Company's drug development programs utilize several cutting-edge approaches, including its industry-leading PEGylation technology platform used to create product candidates with benefits such as reduced dosing frequency and less toxicity. Enzon's PEGylation technology was used to develop two of its products, Oncaspar and Adagen, and has created a royalty revenue stream from licensing partnerships for other products developed using the technology. Enzon also engages in contract manufacturing for several pharmaceutical companies to broaden the Company's revenue base. Further information about Enzon and this press release can be found on the Company's web site at www.enzon.com.

SOURCE: Enzon Pharmaceuticals, Inc.

```
Enzon Pharmaceuticals, Inc.
Craig Tooman, 908-541-8777
EVP, Finance and Chief Financial Officer
```